| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2024 | NBIX Neurocrine Biosciences Inc | Cooke Julie59 | Chief Human Resources Officer | Sell | 10,000 | $140.19 | $1,401,864.00 | -35.5% | -17.8% | -8.6% | |
| Jul 1, 2024 | NBIX Neurocrine Biosciences Inc | Delaet Ingrid67 | Chief Regulatory Officer | Sell | 272 | $138.11 | $37,565.92 | -3.5% | -17.8% | -8.6% | |
| Jul 1, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $319.51 | $2,300,438.97 | -29.5% | +12.3% | -8.8% | |
| Jun 28, 2024 | CGC Canopy Growth Corp | Kruh Willy74 | Director | Sell | 2,012 | $6.41 | $12,896.92 | -11.6% | -29.9% | -81.1% | |
| Jun 28, 2024 | CGC Canopy Growth Corp | Yanofsky Theresa75 | Director | Sell | 1,983 | $6.41 | $12,711.03 | -7.0% | -29.9% | -81.1% | |
| Jun 28, 2024 | CGC Canopy Growth Corp | Mongeau Luc79 | Director | Sell | 2,012 | $6.41 | $12,896.92 | -11.6% | -29.9% | -81.1% | |
| Jun 28, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 1,441 | $915.02 | $1,318,545.26 | - | +0.4% | -14.4% | |
| Jun 28, 2024 | CGC Canopy Growth Corp | Lazzarato David Angelo75 | Director | Sell | 2,986 | $6.41 | $19,140.26 | -8.6% | -29.9% | -81.1% | |
| Jun 27, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, EVP &Treasurer | Sell | 3,596 | $40.93 | $147,169.15 | -1.9% | +15.8% | -42.8% | |
| Jun 27, 2024 | ETST Earth Science Tech, Inc. | Tabraue Mario Guillermo | COO | Buy | 20,000 | $0.23 | $4,600.00 | +0.2% | - | - | |
| Jun 27, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $317.49 | $2,285,941.24 | -32.2% | +13.4% | -10.3% | |
| Jun 26, 2024 | UTHR United Therapeutics Corp | Thompson Tommy G51 | Director | Sell | 7,500 | $319.34 | $2,395,035.38 | -20.7% | +12.2% | -10.9% | |
| Jun 25, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 2,335 | $22.18 | $51,790.30 | -1.3% | -29.0% | +78.8% | |
| Jun 25, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 188,100 | $903.82 | $170,009,262.28 | - | +1.5% | -12.4% | |
| Jun 25, 2024 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 11,546 | $22.21 | $256,489.77 | -6.1% | -29.0% | +78.8% | |
| Jun 25, 2024 | UTHR United Therapeutics Corp | Mesa Nilda47 | Director | Sell | 266 | $318.58 | $84,741.85 | -5.0% | +11.5% | -10.4% | |
| Jun 25, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $317.65 | $2,287,071.99 | -27.2% | +11.5% | -10.4% | |
| Jun 25, 2024 | GTBIF Green Thumb Industries Inc. | Kovler Benjamin | Chairman &CEO | Sell | 35,115 | $12.15 | $426,647.25 | -19.6% | - | - | |
| Jun 25, 2024 | GTBIF Green Thumb Industries Inc. | Georgiadis Anthony | President | Sell | 35,115 | $12.15 | $426,647.25 | -16.9% | - | - | |
| Jun 24, 2024 | HIMS Hims & Hers Health, Inc. | Chi Michael | Chief Commercial Officer | Sell | 17,303 | $22.07 | $381,877.21 | -8.5% | -25.8% | +93.9% | |
| Jun 24, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 17,229 | $902.38 | $15,547,068.30 | - | +3.2% | -12.6% | |
| Jun 24, 2024 | BCRX Biocryst Pharmaceuticals Inc | McKee Amy E | Director | Sell | 8,600 | $6.32 | $54,352.00 | -23.6% | +24.2% | +58.4% | |
| Jun 21, 2024 | ANIP Ani Pharmaceuticals Inc | Shanmugam Muthusamy59 | Head Of R&D, Coo-novitium Ops | Sell | 20,000 | $58.90 | $1,178,000.00 | -2.8% | +3.2% | +12.0% | |
| Jun 21, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $311.44 | $2,242,388.76 | -24.9% | +11.2% | -8.0% | |
| Jun 20, 2024 | HIMS Hims & Hers Health, Inc. | Dudum Andrew47 | Chief Executive Officer | Sell | 45,755 | $22.97 | $1,051,087.28 | -26.2% | -27.2% | +186.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.